EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Early bone marrow alterations in patients with adenosine deaminase 2 deficiency across disease phenotypes and severities

Dimitri Bulté, Federica Barzaghi, Cristina Mesa-Nuñez, Chiara Rigamonti, Luca Basso-Ricci, Camilla Visconti, Stefania Crippa, Emanuela Pettinato, Diego Gilioli, Raffaella Milani, Pamela Quaranta, Roberta Caorsi und 20 weitere

Journal of Allergy and Clinical Immunology · 2025-02 · 155 (2) · 616-627.e8

DOI: 10.1016/j.jaci.2024.09.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025-02. Verfasst von Dimitri Bulté und 31 weiteren Autor:innen. Beteiligte Einrichtung: San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy. Hauptthemen laut MEDLINE: Adenosine Deaminase, Bone Marrow, Intercellular Signaling Peptides and Proteins, Hematopoietic Stem Cells. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero della Salute, Fondazione Telethon, Ospedale Pediatrico Bambino Gesù.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Deficiency of adenosine deaminase 2 (DADA2) is a complex monogenic disease caused by recessive mutations in the ADA2 gene. DADA2 exhibits a broad clinical spectrum encompassing vasculitis, immunodeficiency, and hematologic abnormalities. Yet, the impact of DADA2 on the bone marrow (BM) microenvironment is largely unexplored. OBJECTIVE: This study comprehensively examined the BM and peripheral blood of pediatric and adult patients with DADA2 presenting with rheumatologic/immunologic symptoms or severe hematologic manifestations. METHODS: Immunophenotyping of hematopoietic stem cells (HSCs), progenitor cells, and mature cell populations was performed for 18 patients with DADA2. We also conducted a characterization of mesenchymal stromal cells. RESULTS: Our study revealed a significant decrease in primitive HSCs and progenitor cells, alongside their reduced clonogenic capacity and multilineage differentiation potential. These BM defects were evident in patients with both severe and nonsevere hematologic manifestations, including pediatric patients, demonstrating that BM disruption can emerge silently and early on, even in patients who do not show obvious hematologic symptoms. Beyond stem cells, there was a reduction in mature cell populations in the BM and peripheral blood, affecting myeloid, erythroid, and lymphoid populations. Furthermore, BM mesenchymal stromal cells in patients with DADA2 exhibited reduced clonogenic and proliferation capabilities and were more prone to undergo cellular senescence marked by elevated DNA damage. CONCLUSIONS: Our exploration into the BM landscape of patients with DADA2 sheds light on the critical hematologic dimension of the disease and emphasizes the importance of vigilant monitoring, even in the case of subclinical presentation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine DeaminaseBone MarrowIntercellular Signaling Peptides and ProteinsHematopoietic Stem CellsSevere Combined ImmunodeficiencyAgammaglobulinemiaHumansFemaleChildMaleChild, PreschoolAdolescentAdultPhenotypeInfantYoung AdultImmunophenotypingMesenchymal Stem CellsMiddle Aged

Stichwörter der Autor:innen

Adenosine deaminase 2 deficiencybone marrowbone marrow failurecytopeniahematopoietic stem cell transplantationmesenchymal stromal cellssenescence

Substanzen

Adenosine DeaminaseADA2 protein, humanIntercellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Pediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
  • Immunohematology and Transfusion Medicine Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
  • UOC Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Chromatography and Mass Spectrometry Section, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

Förderung

  • Ministero della Salute
  • Fondazione Telethon
  • Ospedale Pediatrico Bambino Gesù
  • Else Kröner-Fresenius-Stiftung

Zitieren

APA

Bulté, D., Barzaghi, F., Mesa-Nuñez, C., Rigamonti, C., Basso-Ricci, L., Visconti, C., Crippa, S., Pettinato, E., Gilioli, D., Milani, R., Quaranta, P., Caorsi, R., Cafaro, A., Cangemi, G., Lupia, M., Schena, F., Grossi, A., Di Colo, G., Federici, S., …, & Mortellaro, A. (2025). Early bone marrow alterations in patients with adenosine deaminase 2 deficiency across disease phenotypes and severities. Journal of Allergy and Clinical Immunology, 155(2), 616-627.e8. https://doi.org/10.1016/j.jaci.2024.09.007

Vancouver

Bulté D, Barzaghi F, Mesa-Nuñez C, Rigamonti C, Basso-Ricci L, Visconti C, et al. Early bone marrow alterations in patients with adenosine deaminase 2 deficiency across disease phenotypes and severities. Journal of Allergy and Clinical Immunology. 2025;155(2):616-627.e8. doi:10.1016/j.jaci.2024.09.007

BibTeX
@article{Bult2025,
  author = {Bulté, Dimitri and Barzaghi, Federica and Mesa-Nuñez, Cristina and Rigamonti, Chiara and Basso-Ricci, Luca and Visconti, Camilla and Crippa, Stefania and Pettinato, Emanuela and Gilioli, Diego and Milani, Raffaella and Quaranta, Pamela and Caorsi, Roberta and Cafaro, Alessia and Cangemi, Giuliana and Lupia, Michela and Schena, Francesca and Grossi, Alice and Di Colo, Giulia and Federici, Silvia and Insalaco, Antonella and De Benedetti, Fabrizio and Marktel, Sarah and Di Micco, Raffaella and Bernardo, Maria Ester and Scala, Serena and Cicalese, Maria Pia and Conti, Francesca and Miano, Maurizio and Gattorno, Marco and Dufour, Carlo and Aiuti, Alessandro and Mortellaro, Alessandra},
  title = {Early bone marrow alterations in patients with adenosine deaminase 2 deficiency across disease phenotypes and severities},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2025},
  volume = {155},
  number = {2},
  pages = {616--627.e8},
  doi = {10.1016/j.jaci.2024.09.007}
}
Kostenlos starten →